 |
Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium) |
|---|---|
| Trade Name | |
| Orphan Indication | Hepatocellular Carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2016-10-13 00:00:00 |
| Sponsor | Yisheng US Biopharma, Inc.;11 Firstfield Road, Suite A;Gaithersburg, Maryland, 20878 |
